WO2002026745A1 - Composes de thienopyrimidine et leurs sels et procede de preparation - Google Patents
Composes de thienopyrimidine et leurs sels et procede de preparation Download PDFInfo
- Publication number
- WO2002026745A1 WO2002026745A1 PCT/JP2001/008530 JP0108530W WO0226745A1 WO 2002026745 A1 WO2002026745 A1 WO 2002026745A1 JP 0108530 W JP0108530 W JP 0108530W WO 0226745 A1 WO0226745 A1 WO 0226745A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- alkyl
- optionally substituted
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002423981A CA2423981A1 (en) | 2000-09-29 | 2001-09-28 | Thienopyrimidine compounds and salts thereof and process for the preparation of the same |
AU2001290311A AU2001290311A1 (en) | 2000-09-29 | 2001-09-28 | Thienopyrimidine compounds and their salts and process for preparation of both |
JP2002531129A JPWO2002026745A1 (ja) | 2000-09-29 | 2001-09-28 | チエノピリミジン化合物とその塩並びに製造方法 |
EP01970282A EP1329454A1 (en) | 2000-09-29 | 2001-09-28 | Thienopyrimidine compounds and their salts and process for preparation of both |
KR10-2003-7004523A KR20030034232A (ko) | 2000-09-29 | 2001-09-28 | 티에노피리미딘 화합물 및 그 염 및 제조방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-299872 | 2000-09-29 | ||
JP2000299872 | 2000-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002026745A1 true WO2002026745A1 (fr) | 2002-04-04 |
Family
ID=18781622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/008530 WO2002026745A1 (fr) | 2000-09-29 | 2001-09-28 | Composes de thienopyrimidine et leurs sels et procede de preparation |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1329454A1 (ja) |
JP (1) | JPWO2002026745A1 (ja) |
KR (1) | KR20030034232A (ja) |
CN (1) | CN1458933A (ja) |
AU (1) | AU2001290311A1 (ja) |
CA (1) | CA2423981A1 (ja) |
WO (1) | WO2002026745A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006515604A (ja) * | 2003-01-23 | 2006-06-01 | アルミラル プロデスファルマ ソシエダッド アノニマ | Pde7阻害剤としての4−アミノチエノ[2,3−d]ピリミジン−6−カルボニトリル誘導体 |
US7674822B2 (en) | 2004-11-24 | 2010-03-09 | Wyeth | PTP1b inhibitors |
JP2010512337A (ja) * | 2006-12-07 | 2010-04-22 | ジェネンテック インコーポレイテッド | ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法 |
WO2011102399A1 (ja) | 2010-02-17 | 2011-08-25 | 武田薬品工業株式会社 | 複素環化合物 |
US10399951B2 (en) | 2013-03-13 | 2019-09-03 | Forma Therapeutics, Inc. | Compounds and compositions for inhibition of FASN |
US10588894B2 (en) | 2017-06-21 | 2020-03-17 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
US10870657B2 (en) | 2015-12-22 | 2020-12-22 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
US10875848B2 (en) | 2018-10-10 | 2020-12-29 | Forma Therapeutics, Inc. | Inhibiting fatty acid synthase (FASN) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200621257A (en) * | 2004-10-20 | 2006-07-01 | Astellas Pharma Inc | Pyrimidine derivative fused with nonaromatic ring |
US8293754B2 (en) * | 2005-06-14 | 2012-10-23 | Aska Pharmaceutical Co., Ltd. | Thienopyrimidine derivatives |
US20100093714A1 (en) * | 2008-10-13 | 2010-04-15 | Devraj Chakravarty | AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
AU2012340869B2 (en) | 2011-11-23 | 2017-03-02 | Cancer Research Technology Limited | Thienopyrimidine inhibitors of atypical protein kinase C |
CA2860548A1 (en) * | 2012-01-10 | 2013-07-18 | Shaoqing Chen | Thienopyrimidine compounds |
CN103664991B (zh) * | 2012-09-19 | 2016-12-28 | 中国科学院福建物质结构研究所 | 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途 |
WO2019023651A2 (en) | 2017-07-28 | 2019-01-31 | Massachusetts Institute Of Technology | MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR |
SG11202109036WA (en) * | 2019-03-01 | 2021-09-29 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0728759A1 (en) * | 1995-02-24 | 1996-08-28 | Ono Pharmaceutical Co., Ltd. | Heterocyclic compounds |
WO1998006722A1 (de) * | 1996-08-12 | 1998-02-19 | Merck Patent Gmbh | Thienopyrimidine |
WO1998017668A1 (de) * | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine mit pde v inhibierender wirkung |
WO1999028325A1 (de) * | 1997-11-28 | 1999-06-10 | Merck Patent Gmbh | Thienopyrimidine |
-
2001
- 2001-09-28 KR KR10-2003-7004523A patent/KR20030034232A/ko not_active Application Discontinuation
- 2001-09-28 CN CN01815848A patent/CN1458933A/zh active Pending
- 2001-09-28 AU AU2001290311A patent/AU2001290311A1/en not_active Abandoned
- 2001-09-28 EP EP01970282A patent/EP1329454A1/en not_active Withdrawn
- 2001-09-28 JP JP2002531129A patent/JPWO2002026745A1/ja not_active Withdrawn
- 2001-09-28 CA CA002423981A patent/CA2423981A1/en not_active Abandoned
- 2001-09-28 WO PCT/JP2001/008530 patent/WO2002026745A1/ja not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0728759A1 (en) * | 1995-02-24 | 1996-08-28 | Ono Pharmaceutical Co., Ltd. | Heterocyclic compounds |
WO1998006722A1 (de) * | 1996-08-12 | 1998-02-19 | Merck Patent Gmbh | Thienopyrimidine |
WO1998017668A1 (de) * | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine mit pde v inhibierender wirkung |
WO1999028325A1 (de) * | 1997-11-28 | 1999-06-10 | Merck Patent Gmbh | Thienopyrimidine |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006515604A (ja) * | 2003-01-23 | 2006-06-01 | アルミラル プロデスファルマ ソシエダッド アノニマ | Pde7阻害剤としての4−アミノチエノ[2,3−d]ピリミジン−6−カルボニトリル誘導体 |
US7674822B2 (en) | 2004-11-24 | 2010-03-09 | Wyeth | PTP1b inhibitors |
JP2010512337A (ja) * | 2006-12-07 | 2010-04-22 | ジェネンテック インコーポレイテッド | ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法 |
EP3533797A1 (en) | 2010-02-17 | 2019-09-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2011102399A1 (ja) | 2010-02-17 | 2011-08-25 | 武田薬品工業株式会社 | 複素環化合物 |
US8722660B2 (en) | 2010-02-17 | 2014-05-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US8921354B2 (en) | 2010-02-17 | 2014-12-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US8933069B2 (en) | 2010-02-17 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9388195B2 (en) | 2010-02-17 | 2016-07-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9655900B2 (en) | 2010-02-17 | 2017-05-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US10995078B2 (en) | 2013-03-13 | 2021-05-04 | Forma Therapeutics, Inc. | Compounds and compositions for inhibition of FASN |
US10399951B2 (en) | 2013-03-13 | 2019-09-03 | Forma Therapeutics, Inc. | Compounds and compositions for inhibition of FASN |
US10457655B2 (en) | 2013-03-13 | 2019-10-29 | Forma Therapeutics, Inc. | Compounds and compositions for inhibition of FASN |
US10472342B2 (en) | 2013-03-13 | 2019-11-12 | Forma Therapeutics, Inc. | Compounds and compositions for inhibition of FASN |
US10450286B2 (en) | 2013-03-13 | 2019-10-22 | Forma Therapeutics, Inc. | Compounds and compositions for inhibition of FASN |
US10800750B2 (en) | 2013-03-13 | 2020-10-13 | Forma Therapeutics, Inc. | Compounds and compositions for inhibition of FASN |
US11560390B2 (en) | 2015-12-22 | 2023-01-24 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
US10870657B2 (en) | 2015-12-22 | 2020-12-22 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
US11026930B1 (en) | 2017-06-21 | 2021-06-08 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US10933054B2 (en) | 2017-06-21 | 2021-03-02 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US10940139B2 (en) | 2017-06-21 | 2021-03-09 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US11000515B2 (en) | 2017-06-21 | 2021-05-11 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US11213515B1 (en) | 2017-06-21 | 2022-01-04 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US11541041B1 (en) | 2017-06-21 | 2023-01-03 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease |
US10588894B2 (en) | 2017-06-21 | 2020-03-17 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US10875848B2 (en) | 2018-10-10 | 2020-12-29 | Forma Therapeutics, Inc. | Inhibiting fatty acid synthase (FASN) |
US11299484B2 (en) | 2018-10-10 | 2022-04-12 | Forma Therapeutics, Inc. | Inhibiting fatty acid synthase (FASN) |
US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
US11267805B2 (en) | 2018-10-29 | 2022-03-08 | Forma Therapeutics, Inc. | Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone |
Also Published As
Publication number | Publication date |
---|---|
CN1458933A (zh) | 2003-11-26 |
KR20030034232A (ko) | 2003-05-01 |
CA2423981A1 (en) | 2003-03-28 |
JPWO2002026745A1 (ja) | 2004-02-05 |
AU2001290311A1 (en) | 2002-04-08 |
EP1329454A1 (en) | 2003-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014230815B2 (en) | 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | |
TWI620750B (zh) | 新穎之哌啶基衍生物、其製備方法及含其之醫藥組合物 | |
WO2002026745A1 (fr) | Composes de thienopyrimidine et leurs sels et procede de preparation | |
EP2802577B1 (en) | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors | |
EP2411396B1 (en) | Thienopyrimidinedione derivatives as trpa1 modulators | |
EP2464647B1 (en) | Azaindazoles as btk kinase modulators and use thereof | |
JP5350277B2 (ja) | Pi3k阻害剤としてのピロロピリミジン誘導体及びその用途 | |
WO2014128655A1 (en) | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors | |
JP2010511727A (ja) | アデノシン受容体アンタゴニストとしての置換ピリミジン | |
ES2345207T3 (es) | Compuestos pirazolo-heteroarilicos utiles para tratar enfermedades mediadas por tnf-alfa e il-1. | |
CA3006300C (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
JPH06287188A (ja) | 新規複素環誘導体 | |
JP2010511727A5 (ja) | ||
EP2708538A1 (en) | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | |
EP2307411B1 (en) | Triazolopyridine compounds useful as kinase inhibitors | |
US20120108594A1 (en) | PROCESS FOR PREPARING SALTS OF 4-[[5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL]AMINO]-5-METHYL-N-PROPYLPYRROLO[2,1-f][1,2,4]TRIAZINE-6-CARBOXAMIDE AND NOVEL STABLE FORMS PRODUCED THEREIN | |
WO2000059912A1 (fr) | Composes de thienopyrimidine et leurs sels, et procede de preparation desdits composes et sels | |
CN107531695A (zh) | Jak抑制剂 | |
EP3849969B1 (en) | Indazole carboxamides as kinase inhibitors | |
CN108290835B (zh) | Alk和srpk的抑制剂和使用方法 | |
US20110098298A1 (en) | New Pyridin-3-Amine Derivatives | |
JP2006516653A (ja) | キナーゼ阻害剤ピロロトリアジンの製造方法 | |
JP2009524682A (ja) | アナバシン誘導体、医薬組成物およびその使用方法 | |
ES2363672T3 (es) | TRIAZOLO[1,5-a]QUINOLINAS COMO LIGANDOS DEL RECEPTOR A3 DE ADENOSINA. | |
WO1997046560A1 (fr) | Derives d'amides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 01815848X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001290311 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002531129 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037004523 Country of ref document: KR Ref document number: 2423981 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001970282 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037004523 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001970282 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001970282 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020037004523 Country of ref document: KR |